27 completed, 6 recruiting, 6 terminated, 3 withdrawn. 44 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 44 | Completed 27, Recruiting 6, Terminated 6, Withdrawn 3, Active not recruiting 1, Suspended 1 |
| Phase 2 | 22 | Completed 12, Recruiting 4, Terminated 4, Withdrawn 2 |
Follow Nut and Peanut Hypersensitivity: new trials by email Literature Review of Nut and Peanut Hypersensitivity trials Research Report on Nut and Peanut Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of MOON101 for the Treatment of Peanut Allergy Dose A, Dose B, Dose C - Peanut Allergy | Phase 1 | Suspended | Moonlight Therapeutics, Inc. | 40 | 2026-06-29 | 2026-10-16 |
| Single Ascending and Multiple Ascending Dose Study of LCA-0061 LCA-0061, Placebo - Atopic Disease, Peanut Allergies | Phase 1 | Recruiting | Lycia Therapeutics, Inc. | 72 | 2026-06-26 | 2026-07-14 |
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies UKK-0018 - Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Ukko Inc | 40 | 2026-02-18 | 2026-10-16 |
| Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants ENP-501, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | N-Fold, LLC | 68 | 2025-12-16 | 2026-04-24 |
| Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy MY006 Low Dose, MY006 Mid Dose, MY006 High Dose - Peanut Allergies | Phase 1 | Recruiting | Mabylon AG | 48 | 2025-12-06 | 2026-10-20 |
| PK/PD Study of IN-001 Sublingual Spray in Healthy Adults Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray - Food Allergy, Anaphylaxis | Phase 1 | Completed | Insignis Therapeutics, Inc. | 32 | 2025-10-24 | 2026-05-05 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 IGNX001, Placebo - Peanut Allergy | Phase 1 | Completed | IgGenix Australia Pty Ltd | 32 | 2024-09-01 | 2025-11-14 |
| Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects VLP Peanut, Placebo - Peanut Allergy | Phase 1 | Active not recruiting | Allergy Therapeutics | 46 | 2022-10-17 | 2026-03-13 |
| Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy Peanut SLIT-tablet, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | ALK-Abelló A/S | 209 | 2022-09-07 | 2026-05-11 |
| Open-label Extension Study of ADP101 ADP101 - Food Allergy | Phase 1 / Phase 2 | Terminated | Alladapt Immunotherapeutics, Inc. | 45 | 2022-03-14 | 2024-03-26 |
| CNP-201 in Subjects With Peanut Allergy CNP-201, Placebo - Peanut Allergy | Phase 1 | Terminated | COUR Pharmaceutical Development Company, Inc. | 15 | 2022-03-14 | 2023-12-20 |
| Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy Prebiotic, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Completed | University of Chicago | 20 | 2021-11-30 | 2026-03-09 |
| Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy CNP-201, Placebo - Peanut Allergy | Phase 1 | Terminated | COUR Pharmaceutical Development Company, Inc. | 9 | 2021-06-02 | 2023-09-18 |
| OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut INT301, Placebo - Peanut Allergy | Phase 1 | Completed | Intrommune Therapeutics | 32 | 2021-05-15 | 2023-07-28 |
| ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults Low dose ADP101, High dose ADP101, Pooled Placebo - Food Allergy | Phase 1 / Phase 2 | Completed | Alladapt Immunotherapeutics, Inc. | 73 | 2021-04-20 | 2024-05-16 |
| Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy Peanut allergen - Food Allergy Peanut | Phase 1 / Phase 2 | Withdrawn | Scripps Health | 2021-03-01 | 2022-11-22 | |
| Oral Immunotherapy for Peanut Allergic Patients INP20, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | InnoUp Farma S.L. | 50 | 2020-03-11 | 2025-04-30 |
| Boiled Peanut Oral Immunotherapy Boiled Peanut Powder - Peanut Hypersensitivity | Phase 1 | Completed | Alton Melton | 8 | 2019-11-05 | 2024-09-19 |
| VE416 for Treatment of Food Allergy Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Massachusetts General Hospital | 60 | 2019-06-28 | 2023-10-18 |
Showing 20 of 44. Sign in to see all of them.
Peanut Hypersensitivity (42) · Food Hypersensitivity (20) · Hypersensitivity (10) · Hypersensitivity, Immediate (7) · Nut Hypersensitivity (6) · Anaphylaxis (4) · Egg Hypersensitivity (3) · Milk Hypersensitivity (3) · Wheat Hypersensitivity (3) · Immune System Diseases (2) · Shellfish Hypersensitivity (2) · Asthma (1) · Dermatitis, Atopic (1) · Rhinitis, Allergic (1) · Rhinosinusitis (1)
Immune System Diseases (42) · Hypersensitivity, Immediate (37) · Hypersensitivity (34) · Food Hypersensitivity (24) · Bronchial Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis (1) · Genetic Diseases, Inborn (1) · Infections (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Nose Diseases (1) · Otorhinolaryngologic Diseases (1) · Paranasal Sinus Diseases (1)
Omalizumab (3) · Epinephrine (1) · Fecal Microbiota Transplantation (1) · Glycerol (1) · Immunotherapy (1) · Needles (1) · Prebiotics (1) · Vancomycin (1)
University of North Carolina, Chapel Hill (5) · Alladapt Immunotherapeutics, Inc. (2) · Astellas Pharma Global Development, Inc. (2) · COUR Pharmaceutical Development Company, Inc. (2) · DBV Technologies (2) · HAL Allergy (2) · Johns Hopkins University (2) · Massachusetts General Hospital (2) · ALK-Abelló A/S (1) · Allergy Therapeutics (1) · Allertein Therapeutics, LLC (1) · Alton Melton (1) · Baylor College of Medicine (1) · Beth Israel Deaconess Medical Center (1) · Boston Children's Hospital (1)
United States (35) · Australia (3) · Canada (3) · Denmark (1) · New Zealand (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Wesley Burks, MD (5) · Edwin Kim, MD (4) · Robert Wood, MD (4) · Jerry Staser (2) · Mei-Lun Wang, MD (2) · Scott Sicherer, MD (2) · Wayne G Shreffler, MD, PhD (2) · Ana Tabar, PhD, MD (1) · Andrew MacGinnitie, MD, PhD (1) · Andrew T Clark, MB BD MD (1) · Brian P Vickery, MD (1) · Carla M Davis, MD (1) · Carsten Bindslev-Jensen, Prof. Dr. (1) · Christina E Ciaccio, MD (1) · Corinne Keet, MD, MS (1)
PMID 32414772, PMID 33463542, PMID 38010254, PMID 19226304, PMID 21414048, PMID 23265698, PMID 25528358, PMID 25656999, PMID 26920463, PMID 29700872, PMID 31676085, PMID 34755130, PMID 34813505, PMID 39756833, PMID 39842774
2018 (1), R01AT004435 (1), U19AI095261 (1), U44AI165328 (1)